ALS – When the body has given up, but the brain persists

The nerve disease ALS gradually deprives the patient of control over the muscles and, eventually, also of speech. The eyes continue to function, though, and wit...

Svensk obesitaskandidat visade lovande resultat – ”Kan få stor betydelse”

Tabletten ska främja viktminskning utan att påverka aptit eller muskelmassa. Resultaten är lovande, enligt en klinisk fas I-studie från Karolinska institutet oc...

“What is important is to create an overview and understanding from different perspectives”

Scientist Jochen Schwenk analyses blood proteins using proteomics to improve our understanding of disease and health. This year, he is moderating the Lab & Diag...

Are you curious about volume imaging for very large samples?

Exciting ZEISS Webinar!

Automated dispensing

Are you interested in automated dispensing of liquids?

Bioarctic granted Japanese patent for Parkinson’s disease candidate

Bioarctic has been granted a Japanese patent for its antibodies targeting Parkinson’s disease.

On the hunt for high throughput diagnostics

Global diagnostics companies and laboratories are in a race against time to adapt testing capacity to current demand. Due to the global COVID 19 pandemic, the d...

TFS Trial Form Support AB

Studie motbevisar Kennedys påstående om sparkad vaccinkommitté

Den vaccinkommitté som avskedades av Robert F. Kennedy Jr. i början av juni hade lägst nivå av ekonomiska intressekonflikter sedan 2000, visar studie. Tvärtemot...

A billion-dollar acquisition makes Novo Nordisk even bigger in obesity

Danish pharmaceutical giant Novo Nordisk acquires Montreal-based Inversago Pharma, which develops treatments for obesity and diabetes.

Astra Zeneca hoppas på blodtryckskandidat som ny guldgruva

Före årets slut planerar Astra Zeneca att ansöka om regulatoriskt godkännande för sin experimentella blodtrycksbehandling. Förhoppningen är att den på sikt ska ...

Swedish and Ukrainian Medical Product Agencies sign an agreement

The Directors-General of the Swedish and Ukrainian Medical Products Agencies have signed a cooperation agreement.

Lundabolag ansöker om avnotering

Forskningsbolaget Abliva ansöker om avnotering av bolagets aktie från Nasdaq Stockholm.

Business Sweden: “Companies have a lot to offer in data-driven precision medicine”

Data-driven precision medicine can potentially solve major healthcare problems, states Business Sweden in a new report on the subject.

Nanexa develops depot formulation of the diabetes and obesity drug Saxenda

Uppsala-based company Nanexa has signed an agreement with a German contract research company to start a clinical study with a monthly depot of liraglutide. The ...

Quiet, fast, inexpensive: mass flow controller for life sciences

Whether in portable oxygen system devices or in bioreactors, the new proportional flow control valve VEMD from Festo provides extremely high control dynamics an...

Biovica får patent för att förutse immunterapi-effekt

Diagnostikbolaget Biovica har fått ett europeiskt patent beviljat för att förutsäga behandlingseffekt av immunterapier vid cancer med hjälp av företagets produkt Divitum TKa.

Här är artiklarna som lästes mest i augusti

En amerikansk minister som kräver att studier han ogillar återkallas, globala nedskärningar hos två läkemedelsjättar och en myndighet som avböjer pressfrågor – ...

EU Pharmaceutical Legislation Reform

The EU's Pharmaceutical Legislation Reform, proposed by the commission within the European Health Union, aims to establish a citizen-centric framework to enhanc...

Double up for Korbinian Löbmann

This year, Korbinian Löbmann will moderate the New Updates in Drug Formulation & Bioavailability meeting in Copenhagen for the fifth time. Furthermore, he will ...

Gothenburg-based company acquired by Norwegian diagnostics group

Gentian Diagnostics acquires Gothenburg-based Getica.

Bought a tablet factory – and built his own empire

. However, instead, it actually turned out to be the starting point for one of the biggest success stories in Swedish life science.

Suing the company – for NOT developing a new HIV drug

Was Gilead putting a steady flow of profits from its cash cow ahead of developing a new and safer drug? According to a large number of US HIV patients in a lega...

Konsultbolag slås ihop – Scandinavian CRO och Qadvis blir Aurevia

Scandinavian CRO och Qadvis har nu bägge officiellt blivit en del av Aurevia, och tar därmed det nya bolagets namn.